CF33-hNIS has gained FDA orphan drug designation for the treatment of cholangiocarcinoma and is currently being evaluated in ...

In vivo, using the subcutaneous MB49 bladder cancer model, HSV5-15 virus expressing both the cytokine and TLR agonist ...

Replimune's cash runway supports its accelerated approval and phase 3 trial. See why I think REPL's current low stock price ...

Preliminary data presented at ESMO 2024 demonstrate that BT-001 induces tumor regression in patients who failed previous anti-PD(L)-1 treatmentIn a patient with a heavily pretreated leiomyosarcoma, BT ...

BT-001 monotherapy showed stable disease and shrinkage of injected lesions in patients with advanced solid tumors. BT-001 in combination with ...

BT-001 monotherapy showed stable disease and injected lesions shrinkage in advanced solid tumor patients. Promising efficacy ...

Daiichi Sankyo has launched its oncolytic virus therapy Delytact in Japan – its first world market – as a treatment for malignant glioma, an aggressive form of brain cancer.

ImmunityBio's stock has risen sharply this year. Read more on whether investors should look closely at shares or avoid the ...

Results reinforce potential to develop TILT-123 as a systemic therapy in Phase II settingHELSINKI, Sept. 09, 2024 (GLOBE ...

Oncolytic virus BT-001 was shown to replicate and express ... that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently five drug candidates ...

Theriva™ Biologics (NYSE American: TOVX), (“Theriva” or the “Company”) a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet ...